Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.44 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.39 |
| ▸ | PIK3R2 | O00459 | 4/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.39 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19686414 | 0.91 | PIK3R2 (0.40) | PIK3CACCNT1IRAK4PIK3R2SYK | |
| SCHEMBL21165846 | 0.86 | PIK3R2 (0.40) | PIK3CAIRAK4PIK3R2 | |
| SCHEMBL19686418 | 0.84 | IRAK4 (0.38) | PIK3CAIRAK4PIK3R2SYK | |
| SCHEMBL21165913 | 0.78 | IDH1 (0.35) | PIK3R2 | |
| SCHEMBL26604088 | 0.77 | PIK3CA (0.53) | PIK3CACCNT1TTKIRAK4FLT3 | |
| SCHEMBL26604081 | 0.76 | HRH4 (0.57) | PIK3CACCNT1TTKIRAK4FLT3 | |
| SCHEMBL19687111 | 0.75 | HRH4 (0.34) | PIK3R2 | |
| SCHEMBL21144073 | 0.75 | PIK3R2 (0.47) | PIK3R2 | |
| SCHEMBL21165847 | 0.73 | IDH1 (0.36) | IRAK4PIK3R2 | |
| SCHEMBL21165919 | 0.73 | SYK (0.36) | IRAK4SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | PIK3CA 1182/4885CCNT1 4771/4885TTK 2532/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | PIK3CA 1182/4885CCNT1 4771/4885TTK 2532/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | PIK3CA 1182/4885CCNT1 4771/4885TTK 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.